Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Civica Rx Gets $55m Investment

Strikes Deal With Blue Cross Blue Shield Insurance Group

Executive Summary

Civica Rx has won an investment of $55m through a deal with the Blue Cross Blue Shield Association of US health insurance firms to create a new subsidiary that will acquire and develop generic filings to be launched in the US from 2022.

You may also be interested in...



Civica Interested In Retired Or Withdrawn ANDAs

As a part of its strategy to develop its own ANDAs for essential medications, Civica has expressed interest in taking over existing ANDAs that are being retired or withdrawn by other generics manufacturers.

Hikma And Civica Ship Eight Essential Injectables

Hikma and Civica Rx have announced the launch of a first wave of eight essential injectable medicines, including heparin, as part of a deal struck between the two firms earlier this year.

Civica Rx Supplies First Drug In US

A US hospital has received shipment of the first drug to be provided under the affordable generic supply scheme launched by Civica Rx, a nationwide coalition of hospital healthcare groups dedicated to reducing medicine shortages and tackling high prices.

Topics

Related Companies

UsernamePublicRestriction

Register

GB149551

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel